Table 1.
Patient’s demographic and clinical characteristics (enrolled population, n = 149)
| Characteristic | NEPA plus 1-day Dex No. (%) |
|
|---|---|---|
| Age (years) | ||
| Median | 48 | |
| min-max | 25–76 | |
| Age < 50 years | 82 (55) | |
| Height (cm) | ||
| Mean | 162.2 | |
| SD | 6.4 | |
| Weight (kg) | ||
| Mean | 66.9 | |
| SD | 14.5 | |
| ECOG performance status | ||
| 0 | 146 (98) | |
| 1 | 3 (2.0) | |
| Chemotherapy regimen | ||
| AC | 40 (26.8) | |
| EC | 100 (67.1) | |
| FEC | 5 (3.4) | |
| Other/missing | 4 (2.7) | |
| Alcohol consumption | ||
| No | 88 (59.1) | |
| Occasionallya | 42 (28.2) | |
| Regularly | 16 (10.7) | |
| Missing | 3 (2.0) | |
| History of motion sickness | 47 (31.5) | |
| History of pregnancy-related morning sickness | 57 (38.3) | |
NEPA fixed-dose combination of netupitant and palonosetron, Dex dexamethasone, SD standard deviationm, AC anthracycline (i.e., doxorubicin) and cyclophosphamide, EC epirubicin and cyclophosphamide, FEC fluorouracil, epirubicin, and cyclophosphamide
aIt is defined as drinking one or two glasses per week